奥浦迈(688293) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥79,706,760.24, representing a year-on-year increase of 17.36%[5] - Net profit attributable to shareholders decreased by 19.07% to ¥19,578,569.83[5] - The basic earnings per share (EPS) was ¥0.17, down 19.05% compared to the same period last year[5] - Total operating revenue for Q1 2024 reached ¥79,706,760.24, an increase of 17.5% compared to ¥67,917,690.55 in Q1 2023[26] - Operating profit for Q1 2024 decreased to ¥23,105,634.60, down 15.5% from ¥27,374,730.30 in Q1 2023[26] - Net profit for Q1 2024 was ¥23,095,605.32, a decline of 15.8% compared to ¥27,397,124.48 in Q1 2023[26] - The total comprehensive income for Q1 2024 was ¥19,414,232.69, down from ¥24,065,980.32 in Q1 2023, reflecting a decline of 19.3%[27] - Basic and diluted earnings per share for Q1 2024 were both ¥0.17, compared to ¥0.21 in Q1 2023, representing a decrease of 19.0%[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,303,316,756.39, a slight increase of 0.06% from the end of the previous year[5] - Cash and cash equivalents as of March 31, 2024, were ¥1,135,608,947.14, down from ¥1,282,269,233.97 at the end of 2023[24] - Accounts receivable increased to ¥123,013,303.72, up 33.4% from ¥92,224,923.50 at the end of 2023[24] - Total liabilities increased to ¥150,764,849.71, compared to ¥144,205,511.94 at the end of 2023[25] - The company’s total equity as of March 31, 2024, was ¥2,152,551,906.69, a slight decrease from ¥2,157,839,029.12 at the end of 2023[25] Cash Flow - Cash flow from operating activities increased by 25.80% to ¥5,656,507.94[5] - Cash inflows from operating activities totaled ¥63,234,801.20 in Q1 2024, slightly down from ¥64,579,092.78 in Q1 2023, a decrease of 2.1%[30] - Cash outflows from operating activities were ¥57,578,293.26 in Q1 2024, compared to ¥60,082,780.37 in Q1 2023, a decrease of 4.2%[31] - The net cash flow from investing activities was -¥126,280,524.38 in Q1 2024, worsening from -¥90,260,145.10 in Q1 2023[31] - The net cash flow from financing activities was -¥26,162,362.35 in Q1 2024, compared to -¥3,123,849.50 in Q1 2023, indicating a significant increase in cash outflow[31] - The cash and cash equivalents at the end of Q1 2024 were ¥1,135,608,947.14, down from ¥1,416,319,230.30 at the end of Q1 2023, a decrease of 20.0%[32] - The company received ¥198,669,691.50 in cash from investment activities in Q1 2024, compared to ¥271,631,278.60 in Q1 2023, a decrease of 26.9%[31] Research and Development - Research and development (R&D) expenses totaled ¥7,740,448.49, a decrease of 20.43% year-on-year, accounting for 9.71% of revenue[5] - The company reported a decrease in R&D expenses to ¥7,740,448.49 in Q1 2024, down from ¥9,727,974.76 in Q1 2023[26] Sales and Market Performance - Sales expenses rose by 65.47% due to enhanced sales team development and increased personnel costs[10] - Product revenue surged to RMB 71.54 million, reflecting a 71.00% increase year-on-year, while service revenue dropped to RMB 8.05 million, a decline of 69.15%[17] - The company's overseas revenue reached RMB 32.81 million, marking a significant increase of 795.66% year-on-year[18] - The company’s strong performance in the sales of culture media products indicates a stable market demand for high-quality biopharmaceutical raw materials[17] - The company’s strategic focus on enhancing internal capabilities has led to significant improvements in its competitive position within the biopharmaceutical industry[21] Contractual Obligations - The company experienced a significant increase in contract liabilities by 84.49%, attributed to an increase in unfulfilled service contracts[10] Drug Development - The number of drug development pipelines using the company's cell culture products increased to 186, up by 16 from the end of 2023[19] - The company has 105 drug pipelines in the preclinical stage, 34 in Phase I, 22 in Phase II, 22 in Phase III, and 3 in commercial production as of Q1 2024[19] - As of the end of Q1 2024, the company served over 1,400 domestic and international biopharmaceutical enterprises and research institutions[18]